Evotec OAI Appoints Mary Tanner to its Supervisory Board: New Board Member brings significant life science and investment banking expertise

Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced the appointment of Mary C. Tanner to the Company's Supervisory Board with immediate effect.
Mary Tanner brings 22 years of senior level management experience in the healthcare and consumer products industry at Lehman Brothers and Bear Stearns, both global investment banks, to the Company. During that time she led or supervised over 575 transactions, including 220 mergers, acquisitions and divestitures with a total disclosed value of $250+ billion. Mary Tanner also developed a large practice in the biotechnology industry as it emerged over the last 20 years. Ms. Tanner received her university degree from Harvard in 1973 in philosophy and related fields.
Mary Tanner retired from Bear Stearns and founded Life Sciences Partners in 2004, which specialises in healthcare investment and advisory work.
"We are extremely pleased to see Mary Tanner joining the Evotec OAI Supervisory Board," said Prof Heinz Riesenhuber, Chairman of the Evotec OAI Supervisory Board. "Her multi-year senior level life science and investment banking background is a valuable asset for the Company in its strategy to become one of the leading providers of drug candidates to the pharmaceutical industry."
"I am delighted to have the opportunity to support Evotec OAI as a member of the Company's Supervisory Board in this exciting phase of its development," commented Mary Tanner. "With Evotec OAI's leading drug discovery engine, target class know-how and its commitment to increasingly leverage its expertise in discovery programmes in selected indications, the Company is extremely well positioned to become the leading R&D partner for the pharmaceutical industry."
About Evotec OAI AG
Evotec OAI is a leader in the discovery and development of the next generation of novel small molecule based drugs through both contract research partnerships and discovery programmes for out-licensing. The Company provides innovative solutions from Target to Clinic through an unmatched range of integrated capabilities ranging from assay development and screening through to medicinal chemistry and drug manufacturing. As a result, Evotec OAI has established itself as the partner of choice for pharmaceutical and biotechnology companies worldwide. With over 600 people located in Hamburg, Germany and near Oxford, UK, Evotec OAI is committed to generate value to its partners, shareholders and employees through a sustainable strategy that balances short-term and long-term business opportunities.

Contact: Anne Hennecke, Director Investor Relations & Corporate Communications, Evotec OAI AG, Phone: +49-40-56081-286, anne.hennecke@evotecoai.com
Contact: Anne Hennecke, Director Investor Relations & Corporate Communications, Evotec OAI AG, Phone: +49-40-56081-286, anne.hennecke@evotecoai.com